Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2021 09:00 ET | Source: Nabriva Therapeutics US, Inc

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
November 11, 2021 07:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
November 09, 2021 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through...
November 05, 2021 07:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
November 01, 2021 07:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
October 26, 2021 07:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021

DUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
October 15, 2021 16:05 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
October 04, 2021 16:05 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
October 01, 2021 16:05 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
October 01, 2021 07:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical Officer

DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...